Want to see RLYB full AI Analyst Report?
Top Page
Rallybio
(NASDAQ:RLYB)
Select Model
Select Model
Rating:54Neutral
Price Target:
$16.50
▲(1.16% Upside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by weak underlying financial performance (minimal revenue and ongoing operating losses with historically significant cash burn, despite low leverage). Offsetting factors include a constructive technical trend (price above key moving averages with neutral-to-supportive momentum) and a meaningful corporate catalyst (Avenzo merger and $215M financing extending runway), while valuation remains challenged due to negative earnings and no dividend data.
Positive Factors
Balance sheet strength (low leverage)
Near-zero debt meaningfully reduces refinancing and interest-rate risk and preserves financial optionality. For a pre-commercial biotech this durable conservatism supports continued R&D spending or opportunistic partnering/M&A without being constrained by interest obligations.
Negative Factors
Very low revenue and negative operating margins
Rallybio remains pre-commercial with minimal revenue and structurally negative EBIT driven by heavy R&D. Persistent operating losses limit internal funding capacity, necessitate external capital for development, and represent a continuing drag on returns until successful commercialization or asset monetization.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength (low leverage)
Near-zero debt meaningfully reduces refinancing and interest-rate risk and preserves financial optionality. For a pre-commercial biotech this durable conservatism supports continued R&D spending or opportunistic partnering/M&A without being constrained by interest obligations.
Read all positive factors
Rallybio (RLYB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$90.28M
Dividend YieldN/A
Average Volume (3M)283.42K
Price to Earnings (P/E)2.1
Beta (1Y)1.03
Revenue Growth-15.11%
EPS GrowthN/A
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)7.93
Shares Outstanding5,310,499
10 Day Avg. Volume220,035
30 Day Avg. Volume283,421
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.53
Price to Sales (P/S)36.02
P/FCF Ratio-1.04
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Rallybio Business Overview & Revenue Model
Company Description
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoc...
How the Company Makes Money
null...
Rallybio Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
63
Positive
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 646.00K | 858.00K | 636.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.16M | 766.00K | -38.87M | -150.00K | 0.00 | -109.00K |
| EBITDA | 26.96M | -27.97M | -60.37M | -78.78M | -67.72M | -45.39M |
| Net Income | 45.55M | -8.98M | -57.77M | -74.56M | -66.65M | -47.01M |
Balance Sheet | ||||||
| Total Assets | 98.06M | 62.26M | 68.11M | 115.62M | 180.44M | 182.19M |
| Cash, Cash Equivalents and Short-Term Investments | 92.85M | 54.74M | 65.51M | 109.93M | 168.99M | 175.33M |
| Total Debt | 0.00 | 176.00K | 154.00K | 392.00K | 555.00K | 0.00 |
| Total Liabilities | 3.57M | 4.30M | 6.45M | 9.44M | 11.12M | 6.58M |
| Stockholders Equity | 94.50M | 57.96M | 61.65M | 106.18M | 169.32M | 175.60M |
Cash Flow | ||||||
| Free Cash Flow | 26.34M | -29.81M | -49.28M | -60.28M | -57.34M | -45.87M |
| Operating Cash Flow | 26.34M | -29.81M | -49.28M | -60.27M | -57.28M | -45.53M |
| Investing Cash Flow | 56.55M | 47.27M | 33.49M | 27.66M | -112.17M | -2.33M |
| Financing Cash Flow | 150.00K | 16.00K | 5.20M | 143.00K | 51.08M | 82.97M |
Rallybio Technical Analysis
Positive
16.31
Price Trends
16.17
Positive
14.00
Positive
10.12
Positive
Market Momentum
0.23
Negative
54.28
Neutral
55.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLYB, the sentiment is Positive. The current price of 16.31 is below the 20-day moving average (MA) of 16.40, above the 50-day MA of 16.17, and above the 200-day MA of 10.12, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 54.28 is Neutral, neither overbought nor oversold. The STOCH value of 55.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RLYB.
Rallybio Risk Analysis
Rallybio disclosed 82 risk factors in its most recent earnings report. Rallybio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rallybio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $90.28M | 2.09 | 68.56% | ― | -15.11% | ― | |
52 Neutral | $17.50M | -0.28 | -67.42% | ― | ― | 57.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $6.01M | -0.38 | -281.30% | ― | ― | 90.37% | |
46 Neutral | $22.75M | -1.83 | -109.94% | ― | ― | 91.38% | |
45 Neutral | $11.14M | -0.03 | 3114.17% | ― | ― | 85.06% | |
42 Neutral | $4.92M | -0.01 | -198.50% | ― | ― | 99.41% |
* Healthcare Sector Average
RLYB
Rallybio
16.60
11.85
249.33%
MBRX
Moleculin Biotech
0.59
-14.33
-96.04%
APVO
Aptevo Therapeutics
2.76
-34.50
-92.59%
CTXR
Citius Pharmaceuticals
0.60
-0.63
-51.30%
PCSA
Processa Pharmaceuticals
2.15
-3.03
-58.59%
ALLR
Allarity Therapeutics
1.43
0.55
62.50%
Rallybio Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Rallybio to Merge with Avenzo, Shifting to Oncology
Positive
Jun 1, 2026
On May 31, 2026, Rallybio agreed to acquire Avenzo Therapeutics in an all-stock merger that will leave Avenzo shareholders and new private investors owning about 97.2% of the combined company, while existing Rallybio holders will retain roughly 2....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.